Wedbush initiated coverage on shares of Clementia Pharm (NASDAQ:CMTA) in a research note released on Monday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $26.00 price objective on the stock. Wedbush also issued estimates for Clementia Pharm’s Q3 2017 earnings at ($0.30) EPS, Q4 2017 earnings at ($0.31) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($1.62) EPS and FY2021 earnings at ($1.74) EPS.

Separately, Morgan Stanley initiated coverage on shares of Clementia Pharm in a research note on Monday. They issued an overweight rating and a $27.00 price target on the stock.

Shares of Clementia Pharm (CMTA) opened at 16.01 on Monday. Clementia Pharm has a 12 month low of $15.05 and a 12 month high of $18.95. The firm’s 50-day moving average is $14.97 and its 200-day moving average is $14.97. The company’s market cap is $488.74 million.

ILLEGAL ACTIVITY WARNING: “Wedbush Begins Coverage on Clementia Pharm (CMTA)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at

About Clementia Pharm

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related companies with Analyst Ratings Network's FREE daily email newsletter.